We aim to catalyze high-impact research that is critical for advancing the discovery of better treatments for chordoma. To that end, we offer a number of funding opportunities to both academic and industry investigators intended to support research in areas identified as priorities by our Scientific Advisory Board. The following funding opportunities are currently available.
Active funding opportunities
In partnership with the Canadian Cancer Society, this grant is aimed at generating new ideas that lead to critically needed systemic therapies for chordoma. It is specifically designed to support and advance chordoma research in Canada, and will provide grants for up to two meritorious Canadian research projects. Grant budgets may be up to $100,000/year and a maximum of $150,000 per grant over a two-year period. Research priorities include:
- Therapeutic strategies to target brachyury, recently identified as the key vulnerability of chordoma: The transcription factor, brachyury is highly expressed in almost all chordoma tumours and is essential for chordoma cell survival. Identifying upstream regulators and downstream targets of brachyury will uncover novel therapeutic approaches. Strategies to target brachyury itself are also encouraged.
- Application of advances in immune therapy to treat chordoma: Characterization of immune/tumour interactions will identify mechanisms by which chordoma cells evade immune surveillance. This information will shed light on novel immune therapeutic strategies that can be explored to treat this disease.
- Identification of epigenetic strategies to control the disease: Recent evidence has suggested that epigenetic mechanisms contribute to the pathogenesis of chordoma. Characterization of epigenetic alterations may identify novel biomarkers for diagnosis and prognosis as well as therapeutic targets for treatment. Drugs inhibiting these targets may be available for preclinical evaluation in relevant chordoma models.
While additional research topics will be considered aside from the ones listed above, it is strongly encouraged that state of the art technologies and novel strategies be incorporated to achieve the goals of the research plan. It is also hoped that this grant award will foster new collaborations in order to drive translational research findings rapidly to the clinic.
- Abstract registration due date: May 1, 2018
- Relevance review results: end of May 2018
- Full application due date: July 16, 2018
- Results announcement: November 2018
- Anticipated start date: December 1, 2018
An abstract registration guide for the Chordoma Research Grants is available here.
Online applications are accessible through the CCS online research application system EGrAMS. All applications must meet the eligibility requirements.
Relevant areas of study include but are not limited to:
- Interaction of brachyury with other proteins and/or small molecules
- Direct degradation of brachyury
- Functional implications of the chordoma-associated SNP in brachyury
- Therapeutic manipulation of upstream regulators of brachyury, or downstream brachyury targets
- Immunogenic properties of brachyury
- Letter of Intent (LOI): Closed
- Full application due: June 1, 2018
- Award notification: September 2018
RFP and application materials
Inactive funding opportunities
Other funding sources
The organizations listed below have grant programs that accept proposals for chordoma research:
- Conquer Cancer Foundation
- Sarcoma Foundation of America
- Liddy Shriver Sarcoma Initiative
- American Brain Tumor Association
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke